Published November 2, 2018
| Version v1
Report
Open
HAO1 inhibitor development: Screening of follow-up compounds from fragment hits by fluorescence-based activity assay - part 1 of 2
- 1. Structural Genomics Consortium, University of Oxford
Description
This is part of the Open Lab Notebook initiative. To read the associated post please click here.
Notes
Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Files
HAO1 inhibitor development Screening of follow-up compounds from fragment hits by fluorescence-based activity assay - deposition 1 of 2.pdf
Files
(2.0 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:4f0880b3392b8841f648a1915b747f42
|
2.0 MB | Preview Download |